NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.

NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. Abstract Text:

P C Konturek,J Kania,G Burnat,E G Hahn,P C Konturek,J Kania,G Burnat,E G Hahn,

Expression of cyclooxygenase-2 (COX-2) is involved in the chronic inflammation-related development of Barrett's adenocarcinoma and the use of selective COX-2 inhibitors (coxibs) might provide new chemoprevention strategy for Barrett's adenocarcinoma (BA). Despite an excellent gastrointestinal (GI) safety profile of coxibs, their use is limited because of the possible cardiovascular complications. The coupling of NSAIDs with a NO-donating moiety has led to the birth of a new class of anti-inflammatory drugs, called the COX-inhibiting nitric oxide donators (CINODs). The member of this group, NO-aspirin (NO-ASA) retains the anti-inflammatory properties of traditional aspirin (ASA), but the release of NO accounts for anti-thromboembolic effect and better GI safety profile. The role of NO-ASA in the prevention of Barrett's adenocarcinoma (BA) has not been studied so far. Therefore, the aim of the present study was: 1) to analyse the expression of COX-2 in the biopsies obtained from BE; 2) to compare the effect of NO-ASA with that of ASA on proliferation rate in Barrett''s adenocarcinoma cell line (OE-33 cells); 3) to determine the effect of both compounds on the apoptosis rate using FACS analysis and expression of 32-kDa procaspase-3 and active proapoptotic 20-kDa caspase-3 in OE-33 cell line. The expression of COX-2 was assessed in biopsies obtained from the Barrett's mucosa and normal squamous epithelial esophageal mucosa from 20 BE patients by RT-PCR and Western blot analysis, respectively. The BA cell line (OE-33) was incubated with NO-ASA or ASA (10-1000 microM). The cell proliferation and apoptosis rate was measured by BrdU and FACS-analysis, respectively. The expression of caspase-3 (active and inactive form) was analyzed by Western blot. In Barrett's mucosa a significant up-regulation of COX-2 was observed. Compared with traditional ASA, NO-ASA caused a significantly stronger induction of apoptosis (dose-dependently). Inhibition of cell proliferation in OE-33 cells observed under NO-ASA treatment was due to the apoptosis induction. The increase in apoptotic rate was accompanied by the upregulation of active 20-kDa caspase-3. At the highest concentration (1000 microM), a necrotic death of OE-33 cells was observed under NO-ASA treatment. We conclude that: NO-ASA caused induction of apoptosis in BA cell line and slight growth inhibition. These results indicate that this compound may represent a promising chemopreventive agent for Barrett's adenocarcinoma.

NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. Publishing Authors By Initials

PC Konturek,J Kania,G Burnat,EG Hahn,PC Konturek,J Kania,G Burnat,EG Hahn,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Journal of physiology and pharmacology : an offici

VOLUME: 57 Suppl 12

Page Numbers: 15-24

Journal Abbreviation: J. Physiol. Pharmacol.

ISSN: 0867-5910

DAY: 24

MONTH: Dec

YEAR: 2006

NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9114501

NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.

AFFILIATION: First Department of Medicine, University Erlangen-Nuremberg, Erlangen, Germany. pkonturek@web.de

Country: Poland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: J Physiol Pharmacol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin Related Publications

• A comparison of mouse and rabbit embryos for the production of transgenic animals by pronuclear microinjection.
• A pathophysiologic approach to the clinical management of arthritis and pain: current and future implications.
• Antigenicity and immunogenicity of HIV-1 consensus subtype B envelope glycoproteins.
• Attempts to explain and reduce variability of superovulation.
• Behavioral effects of nicotine exposure from secondhand tobacco smoke among bar and restaurant workers.
• CD8+ T cell-mediated suppression of autoimmunity in a murine lupus model of peptide-induced immune tolerance depends on Foxp3 expression.
• CMT1X phenotypes represent loss of GJB1 gene function.
• Comparative proteomic analysis of blue light signaling components in the Arabidopsis cryptochrome 1 mutant.
• Complete extirpation of benign breast lesions with an ultrasound-guided vacuum biopsy system.
• Duodenal mucosal protection by bicarbonate secretion and its mechanisms.
• Economy of mate attraction in the Cassin's finch.
• Estrogen receptor-related receptors in the killifish Fundulus heteroclitus: diversity, expression, and estrogen responsiveness.
• Evaluation of the nephrotoxicity of iodixanol in patients with predisposing factors to contrast medium induced nephropathy referred for contrast enhanced computed tomography.
• Fast mapping skills in the developing lexicon.
• Fate and effects of heavy metals in salt marsh sediments.
• Feasibility of estimating isokinetic knee torque using a neural network model.
• Generation of infectious molecular clones of simian immunodeficiency virus from fecal consensus sequences of wild chimpanzees.
• Imaging spatiotemporal dynamics of Rac activation in vivo with FLAIR.
• Integrative genomic approaches identify IKBKE as a breast cancer oncogene.
• Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.
• Merocyanine dyes with improved photostability.
• NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin.
• Neural aspects of ghrelin-induced gastroprotection against mucosal injury induced by noxious agents.
• Non-compliance in surveillance for patients with previous resection of large (>= 1 cm) colorectal adenomas.
• Polarizability and Kerr constant of proteins by boundary element methods.
• Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.
• Preparation of 14C-Spiro Ethers by Chamomile and their Use by an Investigation of Absorption.
• Primary lymphoma of the central nervous system: a clinical-pathological and immunohistochemical study of ten autopsy cases.
• Simple one-pot preparation of water-soluble, cysteine-reactive cyanine and merocyanine dyes for biological imaging.
• Spatial location and its relevance for terminological inferences in bio-ontologies.